Anteris Technologies Appoints New CFO Brent Moen

What Happened

• Anteris Technologies Global Corp. (AVR) announced the appointment of Brent Moen, age 59, as its Chief Financial Officer, effective September 11, 2026. Mr. Moen has more than 25 years of financial leadership, including prior CFO roles at LifeLens Technologies (Sept 2023–Mar 2026), Tactile Systems Technology (Sept 2018–Apr 2023) and Entellus Medical (May 2016–Mar 2018).
• The company filed an employment agreement with Mr. Moen that outlines base pay, bonus opportunity, equity awards, severance terms and customary confidentiality/non-solicitation and indemnification provisions. Current CFO Matthew McDonnell will cease serving as CFO on September 11, 2026 and will transition to serve as Head of Australia under his existing compensation and benefits.

Key Details

• Base salary: $475,000 per year (effective Sept. 11, 2026).
• Annual bonus: short-term target opportunity up to 50% of base salary (prorated for 2026), subject to performance metrics set by the Board or Compensation Committee.
• Long-term incentive: 2026 equity award with a target value of $500,000 comprised of nonqualified stock options granted Sept. 11, 2026; exercise price = fair market value on grant date; generally vesting in substantially equal installments on each of the first three anniversaries; 10-year term.
• Severance: if terminated by the company without cause (and upon execution of a release), Mr. Moen is eligible for nine months of base-salary continuation and reimbursement of 100% of COBRA premiums for up to nine months.
• No related-party transactions or family relationships were reported in connection with the appointment.

Why It Matters

• Investors get a clear view of the new finance leadership and the compensation structure that aligns Mr. Moen’s pay with company performance (cash salary, bonus opportunity, and a significant equity award).
• The disclosed severance and equity terms are material to executive-costs and executive incentives; the equity grant in particular creates potential future dilution tied to stock performance and is intended to align management and shareholder interests.
• The internal transition of Matthew McDonnell to Head of Australia indicates continuity of personnel while bringing in an experienced finance executive with prior medical-technology CFO experience.